Inhaled Dual PDE3/4 Inhibitor Ensifentrine for Chronic Obstructive Pulmonary Disease: A Potential Therapeutic Perspective

被引：2
|
作者：
Gan, Qiming [1 ]
Wu, Yanjuan [1 ]
Su, Xiaofen [1 ]
Wang, Jingcun [1 ]
Zhang, Haojie [1 ]
Zhang, Nuofu [1 ]
Wu, Kang [1 ]
机构：
[1] Guangzhou Med Univ, Guangzhou Inst Resp Hlth, Natl Ctr Resp Dis, Natl Clin Res Ctr Resp Dis,Affiliated Hosp 1,Stat, Guangzhou, Peoples R China
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷 / 02期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1164/rccm.202307-1143LE
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：223 / 224
页数：3
相关论文
共 50 条
  • [1] Ensifentrine (RPL554): an inhaled "bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease
    Cazzola, Mario
    Page, Clive
    Calzetta, Luigino
    Matera, Maria Gabriella
    PHARMACEUTICAL PATENT ANALYST, 2018, 7 (06) : 249 - 257
  • [2] Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease
    Banner, Katharine H.
    Press, Neil J.
    BRITISH JOURNAL OF PHARMACOLOGY, 2009, 157 (06) : 892 - 906
  • [3] Ensifentrine Dual phosphodiesterase PDE3/4 inhibitor Treatment of COPD Treatment of cystic fibrosis
    Calzetta, L.
    Matera, M. Gabriella
    Rogliani, P.
    Cazzola, M.
    DRUGS OF THE FUTURE, 2019, 44 (11) : 845 - 854
  • [4] Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma
    Bjermer, Leif
    Abbott-Banner, Katharine
    Newman, Kenneth
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2019, 58
  • [5] Ensifentrine, a dual PDE3/PDE4 inhibitor, improves FEV1 regardless of smoking status or history of chronic bronchitis
    Rheault, Tara
    Bengtsson, Thomas
    Rickard, Kathleen
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [6] Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD
    Cazzola, Mario
    Calzetta, Luigino
    Rogliani, Paola
    Matera, Maria Gabriella
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (10) : 827 - 833
  • [7] Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
    Facchinetti, Fabrizio
    Civelli, Maurizio
    Singh, Dave
    Papi, Alberto
    Emirova, Aida
    Govoni, Mirco
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [8] ENSIFENTRINE, AN INVESTIGATIONAL, INHALED PDE3/4 INHIBITOR, DECREASED COPD-RELATED HEALTHCARE RESOURCE UTILIZATION OVER 24 WEEKS
    Wan, E.
    Rickard, K.
    Dixon, A.
    Davidson, J.
    Galloway, S.
    Rheault, T.
    VALUE IN HEALTH, 2024, 27 (06) : S49 - S49
  • [9] Ensifentrine Reduced Healthcare Resource Utilization in Subjects With COPD: Results From Enhance-2, a Phase 3 Trial of Ensifentrine, a Dual PDE3/4 Inhibitor
    Barjaktarevic, I.
    Rheault, T.
    Bengtsson, T.
    Rickard, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [10] Additional Bronchodilation by Ensifentrine, A Dual PDE3/4 Inhibitor, When Combined with a LAMA/LABA in Patients with Moderate to Severe COPD
    Rickard, K.
    Rheault, T.
    Bengtsson, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
12345